Banyu To Sell Facility To Taiho, Move All Research To U.S.
This article was originally published in PharmAsia News
Japan's Banyu Pharmaceutical plans to sell its research facility to Taiho Pharmaceutical, with the deal to be completed by the end of August. Banyu, a subsidiary of U.S.-based Merck, is moving its research work to the United States and assigning its employees at the Japanese facility to other divisions. The Banyu change is part of a global restructuring by Merck. For Taiho, the facility is to serve as its base for developing the cancer drugs in which it specializes. (Click here for more - a subscription may be required
You may also be interested in...
Tokyo-based Taiho Pharmaceutical Nov. 19 announced the European Medicines Agency accepted for review the company's marketing application for the gastric cancer drug S-1
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.